Glenmark Pharmaceuticals Launches Drug To Treat Heart Failure In India

Its approved indication is to reduce the risk of cardiovascular related deaths and hospitalisations for patients with chronic heart failure with HFrEF

Topics

Glenmark Pharmaceuticals | Pharma Companies | Heart Failure

Press Trust of India  |  New Delhi 



Glenmark Pharmaceuticals

').insertAfter(".article-content__img");$(".article-content__img div").find('div').remove();

on Tuesday said it has launched sacubitril and valsartan combination tablets in India for treatment of .

The prescription drug has been launched under brand 'Sacu V' and is priced at Rs 19 per tablet for a dose of 50mg (sacubitril 24mg + valsartan 26mg), Rs 35 per tablet for a dose of 100mg (sacubitril 49mg + valsartan 51mg), and Rs 45 per tablet for a dose of 200mg (sacubitril 97mg + valsartan 103 mg), Glenmark said in a regulatory filing.

EVP & Business Head India Formulations, Alok Malik said Sacu V is an advanced and affordable treatment option, which has been shown to reduce the risk of cardiovascular death or hospitalisation and to improve symptoms associated with with reduced ejection fraction (HFrEF).

The company said Sacu V must be taken twice daily under doctor's prescription. Its approved indication is to reduce the risk of cardiovascular related deaths and hospitalisations for patients with chronic heart failure with HFrEF.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)


Subscribe to Business Standard Premium

Exclusive Stories, Curated Newsletters, 26 years of Archives, E-paper, and more!

First Published: Tue, January 17 2023. 14:41 IST


RECENT NEWS

Coutts Sets Scope On New Continent

Coutts steps into private marketsCoutts, the private bank best known for serving Britain’s wealthiest families and the... Read more

From Cypherpunk To Citadel

How Crypto Moved from the Wild West to the Mainstream Financial SystemA long-form analysis of Bitcoin's journey from fri... Read more

ACB Securities: Building Scale, Trust & Innovation

ACB Securities: Building Scale, Trust and Innovation in Vietnam’s Capital MarketsACB Securities (ACBS) is emerging as ... Read more

War Risk Returns To Markets As VIX Surges

For most of the past year, global markets behaved as though geopolitical risk had largely disappeared. Inflation was eas... Read more

Stablecoin The Future Of Currency?

The payments system is undergoing a quiet but consequential shift. What was once the exclusive preserve of central banks... Read more

BoE Loosens Capital Rules

The Bank of England has taken a significant step towards easing post-crisis regulation by lowering its estimate of the c... Read more